Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
JanOne Inc. (ARCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 06/30/2023 |
8-K
| Changes in Registrant's Certifying Accountant Interactive Data |
| 04/21/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
". IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.",
"JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market LAS VEGAS, March 23, 2023 /PRNewswire/ -- JanOne , a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company’s common stock at a purchase price of $1.17 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 24, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds t...",
"JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market LAS VEGAS, March 24, 2023 /PRNewswire/ -- JanOne , a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced the closing of its previously announced registered direct offering of 361,000 shares of the Company’s common stock at a purchase price of $1.17 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $422,000, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the ne..." |
|
| 03/21/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 11/25/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
8-K
| Quarterly results |
| 06/28/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
| 04/15/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/05/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 10/06/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/06/2021 |
8-K
| Other Events Interactive Data |
| 07/22/2021 |
8-K
| Quarterly results |
| 06/23/2021 |
8-K
| Quarterly results |
| 06/22/2021 |
8-K
| Quarterly results |
| 06/15/2021 |
8-K
| Quarterly results |
| 06/08/2021 |
8-K
| Quarterly results |
| 04/16/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 01/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Placement Agency Agreement, by and between A.G.P./Alliance Global Partners and JanOne Inc",
"Securities Purchase Agreement by and between JanOne Inc. and the purchasers listed therein",
"JanOne Prices $6.0 Million Common Stock Offering Las Vegas, NV, January 29, 2021 — JanOne Inc. , a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common stock at a price of $10.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be $6.0 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about February 2, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acti..." |
|
| 10/01/2020 |
8-K
| Quarterly results |
| 09/24/2020 |
8-K
| Quarterly results |
| 09/21/2020 |
8-K
| Quarterly results |
| 09/16/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/03/2020 |
8-K
| Quarterly results |
|
|
|